## Arrow Pharma Pte Limited

BALANCE SHEET AS AT MARCH 31, 2017

| Note | USD |
| :--- | ---: | ---: |
| No. | 31-Mar-17 |

A ASSETS
I Non-current assets
(a) Property, Plant and Equipment
1
1,668
(b) Financial assets
(i) Investments
Total Non-current assets
II Current assets
(a) Financial assets
(i) Trade receivables

| $\mathbf{2}$ | 141,247 | - |
| ---: | ---: | ---: |
| $\mathbf{3}$ | 94,771 | 29,099 |
| $\mathbf{4}$ | 221,670 | 72,271 |
| $\mathbf{5}$ | 700 | - |
|  | 458,388 | $\mathbf{1 0 1 , 3 6 9}$ |
|  |  |  |

## B EQUITY AND LIABILITIES

## 1 Equity

(a) Equity Share capital
(b) Other equity
Total Equity

| 6 | 72,625 | 72,625 |
| :--- | ---: | ---: |
| 7 | $(156,648)$ | 260,769 |
| $(84,024)$ | 333,393 |  |

II Liabilities
2 Current liabilities
(a) Financials Liabilities
(i) Trade payables
(b) Other current liabilities

| 8 | 127,337 | 4,962 |
| :--- | ---: | ---: |
| 9 | 971,575 | 201,556 |
|  | $\mathbf{1 , 0 9 8 , 9 1 2}$ | $\mathbf{2 0 6 , 5 1 9}$ |
|  | $\mathbf{1 , 0 1 4 , 8 8 8}$ | $\mathbf{5 3 9 , 9 1 2}$ |

See accompanying notes forming part of the Financial Statements

## Note

No.
31-Mar-17
31-Mar-16

1 Revenue from operations
2 Other income
3 Total revenue ( $1+2$ )
4 Expenses
(b) Purchase of stock-in-trade
(a) Employee benefits expenses
(b) Other expenses

Total

5 Earning before exceptional items, interest, tax, depreciation and amortisation (EBITDA) (3-4)

6 Finance costs
7 Depreciation and amortisation expense - - . -

8 Profit before exceptional items and tax (5-6-7)

9 Exceptional items gain / (loss) (net)
10 Profit before tax $(8+9)$
11 Tax expense
12 Profit for the year (10-11)
13 Other Comprehensive Income
A) (i) Items that will not be reclassified to profit or loss
A) (ii) Income tax relating to items that will not be reclassified to profit or loss
B) (i) Items that may be reclassified to profit or loss
B) (ii) Income tax relating to items that may be reclassified to profit or loss

## Total Other comprehensive Income

14 Total Comprehensive Income for the period (12+13)

10

11

|  | 141,420 | - |
| :---: | :---: | :---: |
|  | 121,028 | - |
| 12 | 232,027 | 179,528 |
| 13 | 349,682 | 178,760 |
|  | 702,737 | 358,289 |
|  | $(561,317)$ | $(358,289)$ |

14
1
141,247
173
$(568,417) \quad(360,205)$
$(568,417) \quad(360,205)$

| $(568,417)$ |
| :--- |


| - | - |
| :---: | :---: |
| - | - |
| - | - |
| - | - |
| $\mathbf{~}$ | - |
| $(568,417)$ | $(360,205)$ |

See accompanying notes forming part of the Financial Statements

## Arrow Pharma Pte Limited

Note
No.
2 Trade receivables
USD

| Particulars | 31-Mar-17 | 31-Mar-16 |
| :--- | ---: | :---: |
| Unsecured, considered good |  |  |
| Outstanding for a period exceeding six months from the date they were due for payment |  |  |
| - Unsecured considered good |  |  |
| - Doubtful | - |  |
| Others | - | - |
| - Unsecured considered good | 141,247 | - |
| - Doubtful | - | - |
| Less: Provision for doubtful trade receivables | 141,247 | - |
| Total | - | - |
| Note: Dues from Related Parties | 141,247 | - |

3 Cash and cash equivalents USD

|  | Particulars | 31-Mar-17 |
| :--- | ---: | ---: |
| 31-Mar-16 |  |  |
| Cash in hand | 2,695 | 12,813 |
| Balance with banks in current account | 92,076 | - |
| Deposit | 16,286 |  |
| Total | - |  |

4 Other financial assets USD

| Particulars | 31-Mar-17 | 31-Mar-16 |
| :--- | ---: | ---: |
| Loans and advances to related party | 161,878 | - |
| Loans and advances to fellow subsidiary | $-72,271$ |  |
| Others | - |  |
| Total | 59,793 | - |

5 Other current assets USD

| Particulars | 31-Mar-17 | 31-Mar-16 |
| :--- | :---: | :---: |
| Unsecured, considered good <br> Balances with Government authorities: <br> - Tax deducted at source |  |  |
| Total |  |  |

8 Trade payables USD

| Particulars | 31-Mar-17 | 31-Mar-16 |
| :--- | ---: | ---: |
| Other than acceptances | 127,337 | 4,962 |
| Total | $\mathbf{1 2 7 , 3 3 7}$ | 4,962 |

9 Other current liabilities
USD

| Particulars | 31-Mar-17 | 31-Mar-16 |
| :--- | ---: | ---: |
| Payable to related parties | 971,381 | 201,556 |
| Other current liabilites | 194 | $-\quad$ |
| Total | $\mathbf{9 7 1 , 5 7 5}$ | $\mathbf{2 0 1 , 5 5 6}$ |

Note: 1
Property,plant and equipment as on 31st March 2017
USD

SI No | SI No | Descrip |
| :---: | :--- |
|  | TANGIBLE ASSET |
| 1 | Furniture \& Fixtures |
| 2 |  |

| 2 | Office Equipmen |
| :--- | :--- |
| 3 | Motor Vehicles |

Total Tangible asset
GRAND TOTAL

|  | GROSS BLOCK |
| :---: | :---: |

DEPRECIATION
ET BLOCK
US

|  |  |
| :--- | :--- |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |



Arrow Pharma Pte Limited
STATEMENT OF CHANGES IN EQUITY

| 6 Share capital |
| :--- |
| \begin{tabular}{\|l|c|c|c|}
\hline
\end{tabular} |
| Uuthorised |
| USD |
| Total |
| Issued, subscribed and fully paid-up |
| Equity |
| Preference |
| Total |

## Arrow Pharma Pte Limited STATEMENT OF CHANGES IN EQUITY

7 Other equity
USD

| Particulars | 31-Mar-17 | 31-Mar-16 |
| :---: | :---: | :---: |
| Securities Premium Account <br> Opening Balance <br> Add: Premium on shares issued during the year | - | - |
| Closing balance | - | - |
| Surplus in Statement of Profit and Loss Opening Balance <br> Add: (Loss) for the year | $\begin{aligned} & (360,205) \\ & (568,417) \\ & \hline \end{aligned}$ | $(360,205)$ |
| Closing balance | $(928,623)$ | $(360,205)$ |
| Share application monies pending allotemnt <br> Opening Balance <br> Add: Monies received during the year <br> Less: Share issued/money refunded during the year | $\begin{gathered} 620,974 \\ 151,000 \\ - \\ \hline \end{gathered}$ | $620,974$ |
| Closing balance | 771,974 | 620,974 |
| Other comprehensive income <br> Actuarial gain/(loss) on defined benefit obligation Opening Balance <br> Add/(less): Other comprehensive income for the year <br> Add/(less): Tax impact on the above | - | - |
| Closing balance | - | - |
| Total | $(156,648)$ | 260,769 |


| Note |  |  |  |
| :---: | :---: | :---: | :---: |
| No. |  |  |  |
| 10 | Revenue from operations |  | USD |
|  | Particulars | 31-Mar-17 | 31-Mar-16 |
|  | Sale of product | 141,247 | - |
|  | Total | 141,247 | - |
| 11 | Other income |  | USD |
|  | Particulars | 31-Mar-17 | 31-Mar-16 |
|  | Exchange fluctuation gain (net) | 173 | - |
|  | Total | 173 | - |
| 12 | Employee benefit expenses |  | USD |
|  | Particulars | 31-Mar-17 | 31-Mar-16 |
|  | Salaries and wages | 231,475 | 179,528 |
|  | Contributions to provident and other funds | - | - |
|  | Staff welfare | 552 | - |
|  | Total | 232,027 | 179,528 |
| 13 | Other expenses |  | USD |
|  | Particulars | 31-Mar-17 | 31-Mar-16 |
|  | Power, fuel \& water | 1,453 | 344 |
|  | Conversion \& Processing charges | 225,000 | 110,000 |
|  | Profit on Sale / Disposal of assets | 8,436 | - |
|  | Rent | 12,000 | 7,000 |
|  | Rates \& taxes | 29,458 | 15,853 |
|  | Communication charges | 2,571 | 1,114 |
|  | Repairs \& maintenance |  |  |
|  | - Others | 5,411 | 822 |
|  | Insurance | 317 | - |
|  | Travelling \& conveyance | 49,155 | 24,832 |
|  | Advertisement \& Sellinq expenses | 6,230 | 204 |
|  | Leaal and Professional fees | 9,185 | 11,694 |
|  | Other expenses | 467 | 6,897 |
|  | Total | 349,682 | 178,760 |
| 14 | Finance cost |  | USD |
|  | Particulars | 31-Mar-17 | 31-Mar-16 |
|  | Interest expenses | - | - |
|  | Bank Charges \& Commission | 4,905 | 1,795 |
|  | Total | 4,905 | 1,795 |

